$RVTY

PERKINELMER INC

CIK:0000031791|SEC Filings

Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 05, 2026	Jun. 29, 2025	Jul. 05, 2026	Jun. 29, 2025
Segment revenue	$ 729,688	$ 720,284	$ 1,440,806	$ 1,385,046
Cost of Product and Service Sold	312,822	327,728	636,285	616,944
Selling, general and administrative expenses	278,576	248,526	532,458	498,245
Research and development expenses	48,974	53,270	106,861	106,867
Operating income from continuing operations	89,316	90,760	165,202	162,990
Interest And Other Expense Net	25,785	22,110	51,679	41,958
Income from continuing operations before income taxes	63,531	68,650	113,523	121,032
Provision for income taxes	10,050	13,428	19,149	24,141
Income from continuing operations	53,481	55,222	94,374	96,891
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(1,661)	(1,274)	(1,836)	(706)
Net income	$ 51,820	$ 53,948	$ 92,538	$ 96,185
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 0.48	$ 0.47	$ 0.84	$ 0.82
Gain (loss) on discontinued operations and dispositions (per share)	(0.01)	(0.01)	(0.02)	(0.01)
Net income (per share)	0.47	0.46	0.82	0.81
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	0.48	0.47	0.84	0.82
Gain (loss) on discontinued operations and dispositions (per share)	(0.01)	(0.01)	(0.02)	(0.01)
Net income (per share)	$ 0.47	$ 0.46	$ 0.82	$ 0.81
Weighted average shares of common stock outstanding:
Basic (in shares)	111,584	117,512	111,718	118,824
Diluted (in shares)	111,629	117,538	111,746	118,882
Product [Member]
Segment revenue	$ 603,411	$ 610,704	$ 1,184,869	$ 1,169,758
Cost of Product and Service Sold	264,351	285,593	537,671	533,147
Service [Member]
Segment revenue	126,277	109,580	255,937	215,288
Cost of Product and Service Sold	$ 48,471	$ 42,135	$ 98,614	$ 83,797

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jul. 05, 2026	Jun. 29, 2025
Operating activities:
Net income	$ 92,538	$ 96,185
Loss from discontinued operations, net of income taxes	1,836	706
Income from continuing operations	94,374	96,891
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and other costs	46,183	14,442
Depreciation and amortization	207,095	200,200
Gain on disposition of businesses and assets, net	(5,074)	0
Stock-based compensation	19,446	17,864
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)	1,527	(166)
Amortization of deferred debt financing costs and accretion of discounts	2,440	2,320
Change in fair value of financial securities	9,455	(1,118)
Unrealized Foreign Exchange (Gain) Loss Related to Proceed from Sale of Business	186	140
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	43,916	(21,901)
Inventories	(4,778)	5,642
Accounts payable	(18,064)	3,278
Increase (Decrease) in Accrued Expenses and Other	(78,876)	(49,177)
Net cash provided by operating activities of continuing operations	317,830	268,415
Net cash used in operating activities of discontinued operations	(10,657)	(5,942)
Net cash provided by operating activities	307,173	262,473
Investing activities:
Capital expenditures	(30,848)	(34,850)
Purchases of investments and notes receivables	(3,561)	0
Proceeds from investments and notes receivables	7,496	0
Proceeds from disposition of property, plant and equipment	12,039	0
Proceeds from disposition of businesses and assets	158	229
Cash paid for acquisitions, net of cash acquired	(67,061)	0
Net cash used in investing activities of continuing operations	(81,777)	(34,621)
Net cash provided by investing activities of discontinued operations	0	18,750
Net cash used in investing activities	(81,777)	(15,871)
Financing activities:
Payments of debt financing issuance costs	0	(2,474)
Payments of other credit facilities	0	(103)
Payment for Contingent Consideration Liability, Financing Activities	(350)	(1,978)
Proceeds from issuance of common stock under stock plans	6,437	2,632
Purchases of common stock	(102,488)	(447,501)
Dividends paid	(15,654)	(16,715)
Net cash used in financing activities	(112,055)	(466,139)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(10,190)	48,075
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent	103,151	(171,462)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period	921,030	1,164,452
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period	1,024,181	992,990
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	1,022,943	991,849
Restricted Cash, Current	713	1,141
Restricted Cash, Noncurrent	525	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 1,024,181	$ 992,990

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 05, 2026	Dec. 28, 2025
Current assets:
Cash and cash equivalents	$ 1,022,943	$ 919,860
Accounts receivable, net	709,175	744,671
Inventories, net	378,502	379,497
Other current assets	187,101	195,719
Total current assets	2,297,721	2,239,747
Property, plant and equipment, net:
Property, plant and equipment, net	456,251	479,249
Operating Lease, Right-of-Use Asset	150,945	165,439
Intangible assets, net	2,224,001	2,347,003
Goodwill	6,607,802	6,613,493
Other assets, net	309,114	323,480
Total assets	12,045,834	12,168,411
Current liabilities:
Current portion of long-term debt	572,156	588,828
Accounts payable	165,740	185,464
Accrued expenses and other current liabilities	538,461	556,954
Total current liabilities	1,276,357	1,331,246
Long-term debt	2,633,094	2,631,236
Deferred taxes and other long-term liabilities	771,359	807,461
Operating Lease, Liability, Noncurrent	136,266	148,108
Total liabilities	4,817,076	4,918,051
Commitments and contingencies (see Note 14)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 111,584,000 shares and 112,281,000 shares at July 5, 2026 and December 28, 2025, respectively	111,584	112,281
Capital in excess of par value	1,242,500	1,305,900
Retained earnings	6,131,228	6,054,314
Accumulated other comprehensive loss	(256,554)	(222,135)
Total stockholders’ equity	7,228,758	7,250,360
Total liabilities and stockholders’ equity	$ 12,045,834	$ 12,168,411